Aytu BioPharma Recaps Investor Day, EXXUA Extended-Release Tablets Highlighted

martes, 20 de enero de 2026, 4:07 pm ET1 min de lectura
AYTU--

Aytu BioPharma held an Investor Day on January 20, 2026, to discuss its EXXUA (gepirone) extended-release tablets, the first and only 5-HT1A receptor partial agonist. The company highlighted its commercialization plans and clinical development pipeline for complex central nervous system diseases. A replay of the event is available on the company's website.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios